DDInter1158 DDInter1678
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Mesalazine {u} (Compound) downregulates {v} (Gene) VPS28
VPS28 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Mesalazine {u} (Compound) binds {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Mesalazine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Mesalazine {u} (Compound) downregulates {v} (Gene) CD320
CD320 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Mesalazine {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Mesalazine {u} (Compound) downregulates {v} (Gene) VPS28
VPS28 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Mesalazine {u} (Compound) binds {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Mesalazine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Mesalazine (Compound) downregulates VPS28 (Gene) and VPS28 (Gene) is upregulated by Sirolimus (Compound)
Mesalazine (Compound) binds IKBKB (Gene) and IKBKB (Gene) is upregulated by Sirolimus (Compound)
Mesalazine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Sirolimus (Compound)
Mesalazine (Compound) downregulates CD320 (Gene) and CD320 (Gene) is downregulated by Sirolimus (Compound)
Mesalazine (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may lead to a major life threatening interaction when taken with Sirolimus
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may lead to a major life threatening interaction when taken with Sirolimus
Mesalazine (Compound) downregulates VPS28 (Gene) and VPS28 (Gene) is downregulated by Everolimus (Compound) and Everolimus (Compound) resembles Sirolimus (Compound)
Mesalazine (Compound) binds IKBKB (Gene) and IKBKB (Gene) is upregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Sirolimus (Compound)
Mesalazine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Sirolimus (Compound)